![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/cash-strapped-kiora-sharpens-focus-rare-retinal-diseases-looks-partner-other-assets
https://www.prnewswire.com/news-releases/groundbreaking-clinical-trial-underway-to-improve-vision-in-individuals-with-advanced-retinitis-pigmentosa-rp-301746841.html
https://www.clinicaltrialsarena.com/news/kiora-pced-therapy-trial/
https://ir.kiorapharma.com/news-events/press-releases/detail/165/kiora-pharmaceuticals-announces-publication-of-phase-1
https://ir.kiorapharma.com/news-events/press-releases/detail/164/kiora-pharmaceuticals-regains-compliance-with-nasdaq
https://www.clinicaltrialsarena.com/news/kiora-retinitis-pigmentosa-trial/
https://www.globenewswire.com/news-release/2021/09/08/2293200/0/en/EyeGate-Pharma-Completes-Target-Enrollment-in-Phase-2-Proof-of-Concept-Study-to-Evaluate-PP-001-for-the-Treatment-of-Ocular-Surface-Inflammation.html
https://www.globenewswire.com/news-release/2021/07/26/2268959/0/en/EyeGate-Pharmaceuticals-Announces-Appointment-of-Brian-M-Strem-Ph-D-as-President-and-Chief-Executive-Officer.html
https://www.ophthalmologytimes.com/view/eyegate-pharma-first-patient-dosed-phase-2-ocular-surface-inflammation-study
https://www.globenewswire.com/news-release/2021/05/12/2228705/0/en/EyeGate-Pharma-Reports-First-Quarter-2021-Financial-Results-and-Provides-Business-Update.html